Table 4.
Weibull survival model with random effects in 2131 children on antiretroviral therapy (ART).
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR* | 95% CI | P | aHR | 95% CI | P | |
| Sex | ||||||
| Boys | 1 | - | - | 1 | - | - |
| Girls | 1.1 | 0.7-1.5 | 0.72 | 1.0 | 0.7-1.4 | 0.88 |
| Age at ART initiation | ||||||
| 10 years and plus | 1 | - | - | 1 | - | - |
| [5-10] years | 0.8 | 0.5-1.4 | 0.49 | 0.9 | 0.5-1.5 | 0.70 |
| [3-5] years | 0.6 | 0.3-1.2 | 0.15 | 0.9 | 0.5-1.7 | 0.68 |
| [1-3] years | 1.5 | 0.9-2.6 | 0.12 | 1.2 | 0.7-2.1 | 0.40 |
| < 12 months | 1.2 | 0.4-4.3 | 0.69 | 1.1 | 0.3-3.8 | 0.79 |
| ART regimen at baseline | ||||||
| 2 NRTI+1 NNRTI | 1 | - | - | 1 | ||
| 2 NRTI+1 PI | 0.7 | 0.4-1.0 | 0.06 | 0.9 | 0.6-1.5 | 0.76 |
| Other | 0.2 | 0.02-2.6 | 0.21 | 1.0 | 0.2-5.0 | 0.98 |
| Clinical stage at ART initiation | ||||||
| A, B or I, II, III | 1 | - | - | 1 | - | - |
| AIDS or IV | 6.0 | 3.9-9.2 | < 0.01 | 2.5 | 1.6-3.9 | < 0.01 |
| Unknown | 0.9 | 0.4-2.0 | 0.90 | 1.4 | 0.7-2.9 | 0.29 |
| % CD4 at ART initiation | ||||||
| ≥ 15% | 1 | - | - | 1 | - | - |
| < 15% | 2.1 | 1.1-3.9 | 0.02 | 2.1 | 1.1-4.1 | 0.03 |
| Missing | 1.5 | 0.7-3.3 | 0.22 | 1.5 | 0.6-3.6 | 0.27 |
| Year of ART initiation | ||||||
| ≤ 2004 | 1 | - | - | 1 | - | - |
| 2005 | 1.8 | 1.0-3.0 | 0.03 | 1.7 | 1.0-2.9 | 0.04 |
| ≥ 2006 | 2.6 | 1.7-4.2 | < 0.01 | 2.8 | 1.7-4.7 | < 0.01 |
| Initiation of cotrimoxazole at ART initiation | ||||||
| No | 1 | - | - | 1 | - | - |
| Yes | 1.3 | 0.7-2.5 | 0.39 | 0.9 | 0.5-1.7 | 0.67 |
| Missing | 0.6 | 0.1-3.1 | 0.50 | 0.4 | 0.1-2.3 | 0.30 |
IeDEA paediatric West Africa database (pWADA), 2000-2007. Mortality analysis.
*HR = Hazard Ratio, **95% CI = 95% Confidence Interval, aHR = adjusted Hazard Ratio
Heterogeneity between cohort, p = 0.25